TheracosBio
TheracosBio is a privately held biopharmaceutical company that develops and commercializes Brenzavvy (bexagliflozin), an FDA-approved oral SGLT2 inhibitor for adults with type 2 diabetes, distributed through PBM-free pharmacy channels at transparent pricing of $47.75-$50 per month.
- Company typePrivate
- Founded2000
- HeadquartersFramingham, United States
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What TheracosBio does
TheracosBio is a privately held, single-product biopharmaceutical company headquartered in Framingham, Massachusetts, that develops and commercializes Brenzavvy (bexagliflozin), an oral SGLT2 inhibitor approved by the FDA in January 2023 for glycemic control in adults with type 2 diabetes. Brenzavvy works by inhibiting glucose reabsorption in the kidneys, promoting urinary glucose excretion, and is positioned as a once-daily, lowest-priced SGLT2 inhibitor in the US market following August 2024 IRA negotiated-price disclosures.
The company's business model is built on a PBM-free distribution strategy that bypasses traditional pharmacy benefit managers to deliver transparent pricing at approximately $47.75-$50 per month. Revenue is generated through pharmaceutical product sales across multiple channels, including Mark Cuban Cost Plus Drug Company, DiRx's national online pharmacy, the Independent Pharmacy Cooperative (IPC) serving 7,000+ pharmacies, PBA Health, Publix Pharmacy, and Wellgistics Health's 6,500+ pharmacy network. In August 2023, the company secured royalty financing from HealthCare Royalty (HCRx) to support the consolidated group of companies.
TheracosBio is operated by a lean executive team of approximately eight members covering regulatory affairs, clinical operations, CMC, quality assurance, supply chain, and finance, reflecting a virtual-commercialization model. The company has begun international expansion through a partnership with BAMCO Africa to serve Sub-Saharan Africa and has extended into the B2B marketplace via Cost Plus Drugs Marketplace for healthcare businesses. Revenue figures are not publicly disclosed.
TheracosBio firmographics
Firmographics- Name
- TheracosBio
- Legal name
- TheracosBio, LLC
- Website
- https://theracosbio.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- TheracosBio is a privately held biopharmaceutical company that develops and commercializes Brenzavvy (bexagliflozin), an FDA-approved oral SGLT2 inhibitor for adults with type 2 diabetes, distributed through PBM-free pharmacy channels at transparent pricing of $47.75-$50 per month.
- Ownership category
- akta.pro rank
TheracosBio industry classification
Industry- Product category
- Type 2 Diabetes Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industries
- Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops) (CRAOAHAK), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where TheracosBio is headquartered
LocationHeadquarters
- HQ city
- Framingham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TheracosBio business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Others
Revenue model
- Pharmaceutical Product Sales: Revenue generated from the sale of Brenzavvy (bexagliflozin) through direct pharmacy distribution and pharmacy partners. The company offers transparent pricing at approximately $47.75-$50/month, bypassing PBMs to provide cost savings versus typical insurance copayments.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Monthly | Standard monthly supply through pharmacy partners |
| Transaction based/ take rate | Pay-as-you-go | Healthcare business marketplace pricing |
Go-to-market motion3 records
Distribution channels7 records
Marketing channels4 records
TheracosBio product offering
Product offeringCore offering
TheracosBio develops, manufactures, and distributes Brenzavvy (bexagliflozin), an FDA-approved once-daily oral SGLT2 inhibitor for adults with type 2 diabetes. The company markets the drug at approximately $47.75–$50 per month through PBM-free pharmacy channels, partnering with online pharmacies, independent pharmacy cooperatives, retail chains, and emerging-market distributors to deliver affordable access.
Product overview
TheracosBio is a single-product pharmaceutical company focused on providing affordable medications for prevalent diseases. The company's sole product is Brenzavvy (bexagliflozin), an FDA-approved SGLT2 inhibitor for type 2 diabetes approved in January 2023. The product is distributed through multiple channels including Mark Cuban Cost Plus Drug Company, independent pharmacies via PBA Health and IPC, DiRx online pharmacy, and Wellgistics Health, bypassing traditional PBMs to offer affordable pricing at approximately $47-50 per month.
Differentiator
Problem solved
Functional benefit
Brands
- Brenzavvy (bexagliflozin): FDA-approved oral SGLT2 inhibitor medication for adults with type 2 diabetes, approved by the U.S. Food and Drug Administration in 2023.
Products and services
- Brenzavvy (bexagliflozin) FDA-approved once-daily oral SGLT2 inhibitor for adults with type 2 diabetes that reduces blood sugar and improves glycemic control as an adjunct to diet and exercise, marketed at transparent monthly pricing of $47.75-$50 through PBM-free pharmacy channels for individual patients.
Quantifiable outcome
- Available at $50/month or less through pharmacy partners, below typical insurance copayments
- +3 more outcomes
Companies that use TheracosBio
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles2 records
TheracosBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
TheracosBio partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and major.
- Publix PharmacycoreCollaboration to provide affordably priced FDA-approved diabetes medication (BRENZAVVY) through Publix's retail pharmacy locations, expanding patient access to affordable treatments.
- BAMCO AfricacorePartnership to bring affordably priced BRENZAVVY diabetes medication to Sub-Saharan Africa, expanding access to affordable diabetes care in emerging markets.
- Wellgistics HealthcoreStrategic collaboration to expand access to Brenzavvy (bexagliflozin) through Wellgistics Health's 'maker-to-taker' platform, bypassing pharmacy benefit managers (PBMs) to reduce costs below typical insurance copayments. Partnership covers 6,500+ independent and chain pharmacies nationwide with rollout scheduled for Q4 2025.
- PBA HealthcorePartnership to provide affordably priced FDA-approved BRENZAVVY to thousands of independent community pharmacies through PBA Health's distribution network.
- Independent Pharmacy Cooperative (IPC)coreBRENZAVVY distributed through IPC member pharmacies. IPC is the nation's largest group purchasing organization owned by independent pharmacy, serving more than 7,000 pharmacies. IPC was the first pharmaceutical wholesaler to carry and distribute BRENZAVVY in the US.
- DiRxmajorBRENZAVVY made available through DiRx's national online pharmacy at $47.75/month, eliminating hassles associated with insurance benefit design and providing direct-to-consumer access.
- SmithRxmajorSmithRx offers BRENZAVVY to members with type 2 diabetes through its partnership with Mark Cuban Cost Plus Drug Company, providing PBM-free access to affordable diabetes medication.
- Mark Cuban Cost Plus Drug CompanycoreInitial partnership launched commercial availability of BRENZAVVY at affordable prices. Extended in February 2024 to include healthcare business marketplace access. Cost Plus Drugs provides transparent pricing platform bypassing PBMs.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
TheracosBio competitors and assessment
Company assessmentEmerging players
- Lexicon Pharmaceuticals: Lexicon is a small US biopharma that commercialized an SGLT1/2 inhibitor (Zynquista / sotagliflozin) in diabetes. Comparable to TheracosBio as a smaller, diabetes-focused branded pharma with a single SGLT asset navigating competition against larger incumbents.
- vTv Therapeutics: vTv Therapeutics is a small clinical-stage diabetes-focused biopharma with a single lead asset (cadisegliptin). Comparable to TheracosBio as a small, diabetes-pure-play private or thinly-resourced pharma targeting the same type 2 diabetes market.
- Esperion Therapeutics: Esperion is a small public cardiometabolic biopharma focused on LDL-cholesterol therapies, competing in the same broad cardiometabolic prescriber channel that drives diabetes drugs. Comparable as a small specialized US commercial-stage cardiometabolic company.
- Madrigal Pharmaceuticals: Madrigal is a small US public biopharma with a single cardiometabolic asset (Rezdiffra for MASH). It is comparable to TheracosBio as a focused, single-product cardiometabolic company competing against Big Pharma in a high-prevalence disease category.
Broad incumbents
- Merck (Steglatro / ertugliflozin): Merck markets Steglatro, an SGLT2 inhibitor for type 2 diabetes. It competes in the same drug class as Brenzavvy and is typically co-administered with sitagliptin. Merck is relevant as another large-pharma incumbent competing for the same SGLT2 share-of-voice.
- AstraZeneca (Farxiga / dapagliflozin): AstraZeneca markets Farxiga, the leading SGLT2 inhibitor for type 2 diabetes. TheracosBio directly competes with bexagliflozin in the same drug class, with Farxiga setting the efficacy and pricing benchmark against which Brenzavvy is positioned as a non-inferior, lower-cost alternative.
- Eli Lilly / Boehringer Ingelheim (Jardiance / empagliflozin): Eli Lilly and Boehringer Ingelheim co-market Jardiance, the highest-prescribed SGLT2 inhibitor with established cardiovascular outcomes data. Like Farxiga, Jardiance defines the efficacy comparison against which Brenzavvy demonstrates non-inferiority, and is the primary competitive incumbent in the type 2 diabetes space TheracosBio targets.
- Johnson & Johnson / Janssen (Invokana / canagliflozin): Janssen markets Invokana, the first-approved SGLT2 inhibitor and a direct class competitor to bexagliflozin. Although canagliflozin share has eroded, Janssen's established commercial infrastructure and PBM contracts make it a structural competitor to TheracosBio's PBM-free positioning.
Others
- McKesson Corporation: McKesson is one of the largest pharmaceutical wholesalers in the US and a structural channel counterpart to TheracosBio's IPC, PBA Health, and Wellgistics distribution partners. Relevant as the dominant wholesale distributor model against which TheracosBio's PBM-free/wholesaler-light approach is contrasted.
- Mark Cuban Cost Plus Drug Company: Cost Plus Drugs is TheracosBio's anchor distribution partner and a direct-to-consumer pharmacy that bypasses PBMs. While not a competitor, it is a close ecosystem peer in the PBM-free, affordable-medicine mission and business model that defines TheracosBio's go-to-market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
TheracosBio social profiles
Digital presenceTheracosBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
TheracosBio leadership team
Management profileNumber of profiles
Profiles8 records
TheracosBio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TheracosBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TheracosBio
What does TheracosBio do?
TheracosBio develops, manufactures, and distributes Brenzavvy (bexagliflozin), an FDA-approved once-daily oral SGLT2 inhibitor for adults with type 2 diabetes. The company markets the drug at approximately $47.75–$50 per month through PBM-free pharmacy channels, partnering with online pharmacies, independent pharmacy cooperatives, retail chains, and emerging-market distributors to deliver affordable access.
Is TheracosBio a public or private company?
TheracosBio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was TheracosBio founded?
TheracosBio was founded in 2000. It employs 11 to 50 people.
Where is TheracosBio based?
TheracosBio is headquartered in Framingham, United States, in the North America region.
How does TheracosBio make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are TheracosBio's main competitors?
Emerging players on record are Lexicon Pharmaceuticals, vTv Therapeutics, Esperion Therapeutics and Madrigal Pharmaceuticals. Broad incumbents are Merck (Steglatro / ertugliflozin), AstraZeneca (Farxiga / dapagliflozin), Eli Lilly / Boehringer Ingelheim (Jardiance / empagliflozin) and Johnson & Johnson / Janssen (Invokana / canagliflozin). Others are McKesson Corporation and Mark Cuban Cost Plus Drug Company.
Does TheracosBio have an API?
No public API is recorded for TheracosBio.
What industry is TheracosBio in?
TheracosBio's product category is Type 2 Diabetes Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of CRAOAHAK, Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops). Its NAICS code is 325412 and its SIC code is 2834.